Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Research findings pave new ways to treat gastrointestinal disorders

For those living with gastrointestinal disorders, such as ulcers or Crohn's disease, treatment often means quelling uncomfortable symptoms through medications or dietary changes. But what if one day treatment meant doing away with the old gut for a new gut free of inflamed or diseased tissues?

4 Dec 2013

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Researchers at MIT and Brigham and Women's Hospital have shown that they can grow unlimited quantities of intestinal stem cells, then stimulate them to develop into nearly pure populations of different types of mature intestinal cells. Using these cells, scientists could develop and test new drugs to treat diseases such as ulcerative colitis.

3 Dec 2013

Immune Pharmaceuticals to transfer common stock listing from NASDAQ OMX Stockholm Exchange

Immune Pharmaceuticals Inc. announced today that its common stock has been approved for trading on NASDAQ OMX First North Premier, Stockholm ("First North").

26 Nov 2013

Keeping active reduces women’s Crohn’s risk

Regular exercise protects women against the development of Crohn’s disease, reveals research published in the BMJ.

21 Nov 2013

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

Synergy Pharmaceuticals Inc. today announced the start of the first of two planned phase 3 clinical trials to confirm the safety and efficacy of plecanatide, its lead GC-C agonist and once-daily oral treatment, in adult patients with chronic idiopathic constipation.

13 Nov 2013

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.

11 Nov 2013

Antibe Founder and Chief Science Officer honored with Heymans Foundation Memorial Medal

Antibe Therapeutics Inc. is proud to announce that Dr. John Wallace, the Corporation's Founder and Chief Science Officer, was awarded the Heymans Foundation Memorial Medal in Ghent, Belgium, today.

8 Nov 2013

Researchers identify new class of anti-inflammatory drugs may be used to treat IBD

Researchers in UCD Conway Institute and Systems Biology Ireland have identified a way that a new class of anti-inflammatory drugs may be used to treat inflammatory bowel disease (IBD).

7 Nov 2013

Two long-term policyholders accuse Blue Cross of fraudulent scheme

Blue Cross was sued Monday in Los Angeles Superior Court in separate actions by two long-term policyholders who allege the health insurance giant induced them to switch from grandfathered policies in order to eventually cancel their health insurance.

6 Nov 2013

Study: Interactions between inflammation and changes in gut microbiota may result in colon tumors

Transferring the gut microbes from a mouse with colon tumors to germ-free mice makes those mice prone to getting tumors as well, according to the results of a study published in mBio-, the online open-access journal of the American Society for Microbiology.

6 Nov 2013

Leukemia drug reverses symptoms of colitis in lab tests

A drug currently on the market to treat leukemia reversed symptoms of colitis in lab tests, according to recently published findings by medical researchers with the University of Alberta.

24 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

New study paves way for patient-specific regenerative therapies for inflammatory bowel diseases

A source of gut stem cells that can repair a type of inflammatory bowel disease when transplanted into mice has been identified by researchers at the Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute at the University of Cambridge and at BRIC, the University of Copenhagen, Denmark.

18 Oct 2013

Study shows IBD patients may have increased risk of heart attack, stroke

Patients with inflammatory bowel disease are at an increased risk of stroke and heart attack according to a new study presented by Mayo Clinic researchers at the American College of Gastroenterology's Annual Scientific Meeting, Oct. 11-16, in San Diego.

15 Oct 2013

Change in gene expression occurs in patients with "pouchitis" after UC surgery

"Pouchitis" developing after surgery for ulcerative colitis (UC) is associated with changes in gene expression, which increase along with disease severity, reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

11 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

CementBloc's GROW campaign and campaign for Giazo awarded top honors at MM&M Awards

The CementBloc's Girls Right of Way campaign for The Coore Foundation and "Mr. Butt" campaign for Giazo have been awarded top honors at the MM&M (Medical Marketing & Media) Awards presentation held in New York City on October 2, 2013.

5 Oct 2013

Intestinal mucus potentially improves life of people suffering from inflammatory bowel disease

Researchers at Institut Hospital del Mar d'Investigacions M-diques (IMIM) in Barcelona, in collaboration with the Icahn School of Medicine at Mount Sinai in New York and other U.S. Institutions, have found that intestinal mucus not only acts as a physical barrier against commensal bacteria and dietary antigens, but also prevents the onset of inflammatory reactions against these agents.

27 Sep 2013

Almirall and GKV-SV reach agreement on pricing of Sativex medicine in Germany

...

23 Sep 2013

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

GW Pharmaceuticals plc announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.

18 Sep 2013

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Research findings pave new ways to treat gastrointestinal disorders

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Immune Pharmaceuticals to transfer common stock listing from NASDAQ OMX Stockholm Exchange

Keeping active reduces women’s Crohn’s risk

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

Antibe Founder and Chief Science Officer honored with Heymans Foundation Memorial Medal

Researchers identify new class of anti-inflammatory drugs may be used to treat IBD

Two long-term policyholders accuse Blue Cross of fraudulent scheme

Study: Interactions between inflammation and changes in gut microbiota may result in colon tumors

Leukemia drug reverses symptoms of colitis in lab tests

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

New study paves way for patient-specific regenerative therapies for inflammatory bowel diseases

Study shows IBD patients may have increased risk of heart attack, stroke

Change in gene expression occurs in patients with "pouchitis" after UC surgery

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

CementBloc's GROW campaign and campaign for Giazo awarded top honors at MM&M Awards

Intestinal mucus potentially improves life of people suffering from inflammatory bowel disease

Almirall and GKV-SV reach agreement on pricing of Sativex medicine in Germany

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in